{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:39:40Z","timestamp":1792622380979,"version":"4.5.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"8137","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2026,10,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    New antibodies targeting the F protein of respiratory syncytial virus (RSV) have substantially reduced infant hospitalizations\n                    <jats:sup>1<\/jats:sup>\n                    . However, viral resistance is a concern: one antibody failed clinical trials because of a resistant strain\n                    <jats:sup>2<\/jats:sup>\n                    , and sporadic resistance mutations to the most widely used antibody (nirsevimab) have been identified\n                    <jats:sup>3\u20136<\/jats:sup>\n                    . Here we define how RSV F mutations affect antibody neutralization. We first provide a biophysical model of how the buffering of bivalent IgG binding combines with the lower Fab potency of nirsevimab to subtype B to make resistance to this antibody more common in subtype B than A strains. We then perform pseudovirus deep mutational scanning to safely measure how nearly all mutations to F affect its cell entry function and neutralization by IgG and Fab forms of nirsevimab, clesrovimab and several other key antibodies. We use these measurements to enable real-time surveillance of RSV sequences for antibody resistance, and show that resistant strains have arisen sporadically but are at present rare. Overall, our work shows how Fab potency and epitope specificity combine to determine how viral mutations affect antibody neutralization, enables monitoring for natural RSV strains resistant to antibodies of public-health importance, and can help guide development of future antibodies with resilience to viral escape.\n                  <\/jats:p>","DOI":"10.1038\/s41586-026-11030-4","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:04:48Z","timestamp":1789571088000},"page":"998-1007","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mutational constraints on RSV F and its neutralization by antibodies"],"prefix":"10.1038","volume":"658","author":[{"given":"Cassandra A. L.","family":"Simonich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4215-4717","authenticated-orcid":false,"given":"Teagan E.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Juviler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Kampman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8502-9600","authenticated-orcid":false,"given":"Helen Y.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1267-3408","authenticated-orcid":false,"given":"Jesse D.","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"11030_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.15585\/mmwr.mm7416a1","volume":"74","author":"ME Patton","year":"2025","unstructured":"Patton, M. E. et al. Interim evaluation of respiratory syncytial virus hospitalization rates among infants and young children after introduction of respiratory syncytial virus prevention products \u2014 United States, October 2024\u2013February 2025. MMWR Morb. Mortal. Wkly Rep. 74, 273\u2013281 (2025).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"11030_CR2","doi-asserted-by":"publisher","first-page":"e4400","DOI":"10.1093\/cid\/ciaa951","volume":"73","author":"EAF Sim\u00f5es","year":"2021","unstructured":"Sim\u00f5es, E. A. F. et al. Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants. Clin. Infect. Dis. 73, e4400\u2013e4408 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"11030_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40057-8","volume":"14","author":"B Ahani","year":"2023","unstructured":"Ahani, B. et al. Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials. Nat. Commun. 14, 4347 (2023).","journal-title":"Nat. Commun."},{"key":"11030_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S1473-3099(24)00570-X","volume":"25","author":"S Fourati","year":"2024","unstructured":"Fourati, S. et al. Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study. Lancet Infect. Dis. 25, 301\u2013311 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"11030_CR5","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1093\/infdis\/jiy189","volume":"218","author":"Q Zhu","year":"2018","unstructured":"Zhu, Q. et al. Prevalence and significance of substitutions in the fusion protein of respiratory syncytial virus resulting in neutralization escape from antibody MEDI8897. J. Infect. Dis. 218, 572\u2013580 (2018).","journal-title":"J. Infect. Dis."},{"key":"11030_CR6","doi-asserted-by":"publisher","first-page":"101353","DOI":"10.1016\/j.lanmic.2026.101353","volume":"7","author":"S Fourati","year":"2026","unstructured":"Fourati, S. et al. Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France. Lancet Microbe 7, 101353 (2026).","journal-title":"Lancet Microbe"},{"key":"11030_CR7","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","volume":"399","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 399, 2047\u20132064 (2022).","journal-title":"Lancet"},{"key":"11030_CR8","doi-asserted-by":"publisher","first-page":"S154","DOI":"10.1093\/infdis\/jiac120","volume":"226","author":"M Suh","year":"2022","unstructured":"Suh, M. et al. Respiratory syncytial virus is the leading cause of United States infant hospitalizations, 2009\u20132019: a study of the national (nationwide) inpatient sample. J. Infect. Dis. 226, S154\u2013S163 (2022).","journal-title":"J. Infect. Dis."},{"key":"11030_CR9","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2025-073923","volume":"156","author":"Committee on Infectious Diseases.","year":"2025","unstructured":"Committee on Infectious Diseases. Recommendations for the prevention of RSV disease in infants and children: policy statement. Pediatrics 156, e2025073923 (2025).","journal-title":"Pediatrics"},{"key":"11030_CR10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2352-4642(25)00093-8","volume":"9","author":"DM Sumsuzzman","year":"2025","unstructured":"Sumsuzzman, D. M., Wang, Z., Langley, J. M. & Moghadas, S. M. Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis. Lancet Child Adolesc. Health 9, 393\u2013403 (2025).","journal-title":"Lancet Child Adolesc. Health"},{"key":"11030_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-10120-w","volume":"24","author":"A Bonavia","year":"2024","unstructured":"Bonavia, A. et al. RSM01, a novel respiratory syncytial virus monoclonal antibody: preclinical characterization and results of a first-in-human, randomised clinical trial. BMC Infect. Dis. 24, 1378 (2024).","journal-title":"BMC Infect. Dis."},{"key":"11030_CR12","doi-asserted-by":"publisher","first-page":"e70257","DOI":"10.1111\/pai.70257","volume":"36","author":"E Bizot","year":"2025","unstructured":"Bizot, E. et al. Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: an in-depth review of mechanisms of action, failure factors, and future perspectives. Pediatr. Allergy Immunol. 36, e70257 (2025).","journal-title":"Pediatr. Allergy Immunol."},{"key":"11030_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj1928","volume":"9","author":"Q Zhu","year":"2017","unstructured":"Zhu, Q. et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci. Transl. Med. 9, eaaj1928 (2017).","journal-title":"Sci. Transl. Med."},{"key":"11030_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12137-1","volume":"10","author":"A Tang","year":"2019","unstructured":"Tang, A. et al. A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein. Nat. Commun. 10, 4153 (2019).","journal-title":"Nat. Commun."},{"key":"11030_CR15","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1016\/j.chom.2023.09.012","volume":"31","author":"KE Kistler","year":"2023","unstructured":"Kistler, K. E. & Bedford, T. An atlas of continuous adaptive evolution in endemic human viruses. Cell Host Microbe 31, 1898\u20131909 (2023).","journal-title":"Cell Host Microbe"},{"key":"11030_CR16","doi-asserted-by":"publisher","first-page":"e0175792","DOI":"10.1371\/journal.pone.0175792","volume":"12","author":"AM Hause","year":"2017","unstructured":"Hause, A. M. et al. Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV\/A and RSV\/B. PLOS ONE 12, e0175792 (2017).","journal-title":"PLOS ONE"},{"key":"11030_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25265-4","volume":"12","author":"G-L Lin","year":"2021","unstructured":"Lin, G.-L. et al. Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus. Nat. Commun. 12, 5125 (2021).","journal-title":"Nat. Commun."},{"key":"11030_CR18","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s40121-024-01012-2","volume":"13","author":"C Nuttens","year":"2024","unstructured":"Nuttens, C. et al. Differences between RSV A and RSV B subgroups and implications for pharmaceutical preventive measures. Infect. Dis. Ther. 13, 1725\u20131742 (2024).","journal-title":"Infect. Dis. Ther."},{"key":"11030_CR19","unstructured":"US Food and Drug Administration. Beyfortus (Nirsevimab-Alip) prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761328s000lbl.pdf (2025)."},{"key":"11030_CR20","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/S1473-3099(23)00062-2","volume":"23","author":"D Wilkins","year":"2023","unstructured":"Wilkins, D. et al. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data. Lancet Infect. Dis. 23, 856\u2013866 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"11030_CR21","doi-asserted-by":"publisher","first-page":"106153","DOI":"10.1016\/j.jinf.2024.106153","volume":"88","author":"M Pi\u00f1ana","year":"2024","unstructured":"Pi\u00f1ana, M. et al. Genomic evolution of human respiratory syncytial virus during a decade (2013\u20132023): bridging the path to monoclonal antibody surveillance. J. Infect. 88, 106153 (2024).","journal-title":"J. Infect."},{"key":"11030_CR22","doi-asserted-by":"publisher","unstructured":"Terstappen, J. et al. RSM01, an extended half-life RSV monoclonal antibody with a high barrier to resistance. Preprint at bioRxiv https:\/\/doi.org\/10.64898\/2026.02.04.703721 (2026).","DOI":"10.64898\/2026.02.04.703721"},{"key":"11030_CR23","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1126\/science.1234914","volume":"340","author":"JS McLellan","year":"2013","unstructured":"McLellan, J. S. et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340, 1113\u20131117 (2013).","journal-title":"Science"},{"key":"11030_CR24","doi-asserted-by":"publisher","first-page":"294","DOI":"10.20411\/pai.v4i2.338","volume":"4","author":"MG Joyce","year":"2019","unstructured":"Joyce, M. G. et al. Crystal structure and immunogenicity of the DS-Cav1-stabilized fusion glycoprotein from respiratory syncytial virus subtype B. Pathog. Immun. 4, 294 (2019).","journal-title":"Pathog. Immun."},{"key":"11030_CR25","doi-asserted-by":"crossref","unstructured":"McLellan, J. S., Ray, W. C. & Peeples, M. E. in Challenges and Opportunities for Respiratory Syncytial Virus Vaccines Vol. 372 (eds Anderson, L. J. & Graham, B. S.) 83\u2013104 (Springer, 2013).","DOI":"10.1007\/978-3-642-38919-1_4"},{"key":"11030_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54384-x","volume":"15","author":"Y Sun","year":"2024","unstructured":"Sun, Y. et al. A potent broad-spectrum neutralizing antibody targeting a conserved region of the prefusion RSV F protein. Nat. Commun. 15, 10085 (2024).","journal-title":"Nat. Commun."},{"key":"11030_CR27","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.57264","volume":"9","author":"I Jarmoskaite","year":"2020","unstructured":"Jarmoskaite, I., AlSadhan, I., Vaidyanathan, P. P. & Herschlag, D. How to measure and evaluate binding affinities. eLife 9, e57264 (2020).","journal-title":"eLife"},{"key":"11030_CR28","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.cels.2019.09.007","volume":"9","author":"T Einav","year":"2019","unstructured":"Einav, T., Yazdi, S., Coey, A., Bjorkman, P. J. & Phillips, R. Harnessing avidity: quantifying the entropic and energetic effects of linker length and rigidity for multivalent binding of antibodies to HIV-1. Cell Syst. 9, 466\u2013474 (2019).","journal-title":"Cell Syst."},{"key":"11030_CR29","doi-asserted-by":"publisher","first-page":"e1000908","DOI":"10.1371\/journal.ppat.1000908","volume":"6","author":"JS Klein","year":"2010","unstructured":"Klein, J. S. & Bjorkman, P. J. Few and far between: how HIV may be evading antibody avidity. PLOS Pathog. 6, e1000908 (2010).","journal-title":"PLOS Pathog."},{"key":"11030_CR30","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.cell.2023.02.001","volume":"186","author":"B Dadonaite","year":"2023","unstructured":"Dadonaite, B. et al. A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike. Cell 186, 1263\u20131278 (2023).","journal-title":"Cell"},{"key":"11030_CR31","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00531-25","volume":"99","author":"CAL Simonich","year":"2025","unstructured":"Simonich, C. A. L. et al. RSV F evolution escapes some monoclonal antibodies but does not strongly erode neutralization by human polyclonal sera. J. Virol. 99, e00531-25 (2025).","journal-title":"J. Virol."},{"key":"11030_CR32","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.03074-24","volume":"16","author":"A Casadevall","year":"2025","unstructured":"Casadevall, A., Roane, P. R., Shenk, T. & Roizman, B. The story behind the science: on the discovery of respiratory syncytial virus. mBio 16, e03074-24 (2025).","journal-title":"mBio"},{"key":"11030_CR33","doi-asserted-by":"publisher","first-page":"E7550","DOI":"10.1073\/pnas.1804015115","volume":"115","author":"J Otwinowski","year":"2018","unstructured":"Otwinowski, J., McCandlish, D. M. & Plotkin, J. B. Inferring the shape of global epistasis. Proc. Natl Acad. Sci. USA 115, E7550\u2013E7558 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"11030_CR34","doi-asserted-by":"publisher","unstructured":"Haddox, H. K. et al. Jointly modeling deep mutational scans identifies shifted mutational effects among SARS-CoV-2 spike homologs. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.07.31.551037 (2023).","DOI":"10.1101\/2023.07.31.551037"},{"key":"11030_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aaj1879","volume":"1","author":"MSA Gilman","year":"2016","unstructured":"Gilman, M. S. A. et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci. Immunol. 1, eaaj1879 (2016).","journal-title":"Sci. Immunol."},{"key":"11030_CR36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.tim.2017.09.009","volume":"26","author":"I Rossey","year":"2018","unstructured":"Rossey, I., McLellan, J. S., Saelens, X. & Schepens, B. Clinical potential of prefusion RSV F-specific antibodies. Trends Microbiol. 26, 209\u2013219 (2018).","journal-title":"Trends Microbiol."},{"key":"11030_CR37","doi-asserted-by":"publisher","first-page":"920","DOI":"10.15585\/mmwr.mm7234a4","volume":"72","author":"JM Jones","year":"2023","unstructured":"Jones, J. M. et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023. MMWR Morb. Mortal. Wkly Rep. 72, 920\u2013925 (2023).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"11030_CR38","doi-asserted-by":"publisher","first-page":"13961","DOI":"10.1073\/pnas.94.25.13961","volume":"94","author":"RA Karron","year":"1997","unstructured":"Karron, R. A. et al. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc. Natl Acad. Sci. USA 94, 13961\u201313966 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"11030_CR39","doi-asserted-by":"publisher","first-page":"508","DOI":"10.15585\/mmwr.mm7432a3","volume":"74","author":"DL Moulia","year":"2025","unstructured":"Moulia, D. L. et al. Use of clesrovimab for prevention of severe respiratory syncytial virus\u2013associated lower respiratory tract infections in infants: recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2025. MMWR Morb. Mortal. Wkly Rep. 74, 508\u2013514 (2025).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"11030_CR40","unstructured":"US Food and Drug Administration. ENFLONSIA (Clesrovimab-Cfor) prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761432s000lbl.pdf (2025)."},{"key":"11030_CR41","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01828-20","volume":"59","author":"DE Tabor","year":"2020","unstructured":"Tabor, D. E. et al. Global molecular epidemiology of respiratory syncytial virus from the 2017\u22122018 INFORM-RSV study. J. Clin. Microbiol. 59, e01828-20 (2020).","journal-title":"J. Clin. Microbiol."},{"key":"11030_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40387-y","volume":"9","author":"B. Lu","year":"2019","unstructured":"Lu, B. et al. Emergence of new antigenic epitopes in the glycoproteins of human respiratory syncytial virus collected from a US surveillance study, 2015\u201317. Sci. Rep. 9, 3898 (2019).","journal-title":"Sci. Rep."},{"key":"11030_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/irv.70164","volume":"19","author":"M Wetzke","year":"2025","unstructured":"Wetzke, M. et al. Prevalence of resistance-associated mutations in RSV F protein against monoclonal antibodies prior to widespread implementation: findings from a prospective German pediatric cohort. Influenza Other Respir. Viruses 19, e70164 (2025).","journal-title":"Influenza Other Respir. Viruses"},{"key":"11030_CR44","doi-asserted-by":"publisher","unstructured":"Iglesias-Caballero, M. et al. Genomic surveillance and antigenic characterization of respiratory syncytial virus (RSV) in Spain during the 2023-2024 season of nirsevimab administration. J. Infect. Dis. 223, jiaf530 https:\/\/doi.org\/10.1093\/infdis\/jiaf530 (2025).","DOI":"10.1093\/infdis\/jiaf530"},{"key":"11030_CR45","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1093\/bioinformatics\/bty407","volume":"34","author":"J Hadfield","year":"2018","unstructured":"Hadfield, J. et al. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics 34, 4121\u20134123 (2018).","journal-title":"Bioinformatics"},{"key":"11030_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2024.100995","volume":"5","author":"ED Vecchia","year":"2024","unstructured":"Vecchia, E. D. Pathoplexus: towards fair and transparent sequence sharing. Lancet Microbe 5, 100995 (2024).","journal-title":"Lancet Microbe"},{"key":"11030_CR47","doi-asserted-by":"crossref","unstructured":"The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102, 531\u2013537 (1998).","DOI":"10.1542\/peds.102.3.531"},{"key":"11030_CR48","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/infdis\/jir790","volume":"205","author":"Q Zhu","year":"2012","unstructured":"Zhu, Q. et al. Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab. J. Infect. Dis. 205, 635\u2013638 (2012).","journal-title":"J. Infect. Dis."},{"key":"11030_CR49","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/infdis\/jiq100","volume":"203","author":"Q Zhu","year":"2011","unstructured":"Zhu, Q. et al. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and\/or motavizumab. J. Infect. Dis. 203, 674\u2013682 (2011).","journal-title":"J. Infect. Dis."},{"key":"11030_CR50","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.virol.2003.10.018","volume":"318","author":"X Zhao","year":"2004","unstructured":"Zhao, X., Chen, F.-P. & Sullender, W. M. Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology 318, 608\u2013612 (2004).","journal-title":"Virology"},{"key":"11030_CR51","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1086\/653534","volume":"51","author":"O Adams","year":"2010","unstructured":"Adams, O. et al. Palivizumab-resistant human respiratory syncytial virus infection in infancy. Clin. Infect. Dis. 51, 185\u2013188 (2010).","journal-title":"Clin. Infect. Dis."},{"key":"11030_CR52","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ady2450","volume":"18","author":"Y Sun","year":"2026","unstructured":"Sun, Y. et al. An antibody cocktail targeting conserved, nonoverlapping epitopes prevents viral escape and confers protection against RSV in vivo. Sci. Transl. Med. 18, eady2450 (2026).","journal-title":"Sci. Transl. Med."},{"key":"11030_CR53","unstructured":"US Food and Drug Administration. Antiviral Product Development\u2014Conducting and Submitting Virology Studies to the Agency (FDA, 2006)."},{"key":"11030_CR54","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1126\/science.1187816","volume":"328","author":"JD Bloom","year":"2010","unstructured":"Bloom, J. D., Gong, L. I. & Baltimore, D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328, 1272\u20131275 (2010).","journal-title":"Science"},{"key":"11030_CR55","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/molbev\/msm103","volume":"24","author":"L Simonsen","year":"2007","unstructured":"Simonsen, L. et al. The genesis and spread of reassortment human influenza A\/H3N2 viruses conferring adamantane resistance. Mol. Biol. Evol. 24, 1811\u20131820 (2007).","journal-title":"Mol. Biol. Evol."},{"key":"11030_CR56","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1098\/rsif.2011.0427","volume":"9","author":"DL Chao","year":"2012","unstructured":"Chao, D. L., Bloom, J. D., Kochin, B. F., Antia, R. & Longini, I. M. The global spread of drug-resistant influenza. J. R. Soc. Interface 9, 648\u2013656 (2012).","journal-title":"J. R. Soc. Interface"},{"key":"11030_CR57","doi-asserted-by":"publisher","first-page":"e2533535","DOI":"10.1001\/jamanetworkopen.2025.33535","volume":"8","author":"JH Pelletier","year":"2025","unstructured":"Pelletier, J. H. et al. Nirsevimab administration and RSV hospitalization in the 2024-2025 season. JAMA Netw. Open 8, e2533535 (2025).","journal-title":"JAMA Netw. Open"},{"key":"11030_CR58","doi-asserted-by":"publisher","first-page":"484","DOI":"10.15585\/mmwr.mm7431a3","volume":"74","author":"EO Boundy","year":"2025","unstructured":"Boundy, E. O. et al. Respiratory syncytial virus immunization coverage among infants through receipt of nirsevimab monoclonal antibody or maternal vaccination \u2014 United States, October 2023\u2013March 2024. MMWR Morb. Mortal. Wkly Rep. 74, 484\u2013489 (2025).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"11030_CR59","doi-asserted-by":"publisher","first-page":"1184362","DOI":"10.3389\/fimmu.2023.1184362","volume":"14","author":"D Cantoni","year":"2023","unstructured":"Cantoni, D. et al. Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature. Front. Immunol. 14, 1184362 (2023).","journal-title":"Front. Immunol."},{"key":"11030_CR60","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.omtm.2020.10.020","volume":"20","author":"D Humes","year":"2021","unstructured":"Humes, D., Rainwater, S. & Overbaugh, J. The TOP vector: a new high-titer lentiviral construct for delivery of sgRNAs and transgenes to primary T cells. Mol. Ther. Methods Clin. Dev. 20, 30\u201338 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"11030_CR61","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.chom.2025.04.018","volume":"33","author":"AK Aditham","year":"2025","unstructured":"Aditham, A. K. et al. Deep mutational scanning of rabies glycoprotein defines mutational constraint and antibody-escape mutations. Cell Host Microbe 33, 988\u20131003 (2025).","journal-title":"Cell Host Microbe"},{"key":"11030_CR62","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1093\/molbev\/msu173","volume":"31","author":"JD Bloom","year":"2014","unstructured":"Bloom, J. D. An experimentally determined evolutionary model dramatically improves phylogenetic fit. Mol. Biol. Evol. 31, 1956\u20131978 (2014).","journal-title":"Mol. Biol. Evol."},{"key":"11030_CR63","doi-asserted-by":"publisher","first-page":"e3002916","DOI":"10.1371\/journal.pbio.3002916","volume":"22","author":"B Dadonaite","year":"2024","unstructured":"Dadonaite, B. et al. Deep mutational scanning of H5 hemagglutinin to inform influenza virus surveillance. PLOS Biol. 22, e3002916 (2024).","journal-title":"PLOS Biol."},{"key":"11030_CR64","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41559-025-02895-1","volume":"10","author":"TC Yu","year":"2025","unstructured":"Yu, T. C. et al. Pleiotropic mutational effects on function and stability constrain the antigenic evolution of influenza haemagglutinin. Nat. Ecol. Evol. 10, 452\u2013466 (2025).","journal-title":"Nat. Ecol. Evol."},{"key":"11030_CR65","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.21105\/joss.01915","volume":"4","author":"K Crawford","year":"2019","unstructured":"Crawford, K. & Bloom, J. alignparse: a Python package for parsing complex features from high-throughput long-read sequencing. J. Open Source Softw. 4, 1915 (2019).","journal-title":"J. Open Source Softw."},{"key":"11030_CR66","doi-asserted-by":"publisher","DOI":"10.1093\/ve\/veac110","volume":"8","author":"TC Yu","year":"2022","unstructured":"Yu, T. C. et al. A biophysical model of viral escape from polyclonal antibodies. Virus Evol. 8, veac110 (2022).","journal-title":"Virus Evol."},{"key":"11030_CR67","doi-asserted-by":"publisher","unstructured":"Simonich, C. A. L. et al. SeqSet: RSV_F_DMS_Validations. Pathoplexus https:\/\/doi.org\/10.62599\/PP_SS_628.1 (2026).","DOI":"10.62599\/PP_SS_628.1"},{"key":"11030_CR68","doi-asserted-by":"publisher","unstructured":"Simonich, C. A. L. et al. SeqSet: RSV_A_F_sequences_for_tree. Pathoplexus https:\/\/doi.org\/10.62599\/PP_SS_661.1 (2026).","DOI":"10.62599\/PP_SS_661.1"},{"key":"11030_CR69","doi-asserted-by":"publisher","unstructured":"Simonich, C. A. L. et al. SeqSet: RSV_B_F_sequences_for_tree. Pathoplexus https:\/\/doi.org\/10.62599\/PP_SS_662.1 (2026).","DOI":"10.62599\/PP_SS_662.1"},{"key":"11030_CR70","doi-asserted-by":"publisher","first-page":"e4792","DOI":"10.1002\/pro.4792","volume":"32","author":"EC Meng","year":"2023","unstructured":"Meng, E. C. et al. UCSF ChimeraX: Tools for structure building and analysis. Protein Sci. 32, e4792 (2023).","journal-title":"Protein Sci."},{"key":"11030_CR71","doi-asserted-by":"publisher","unstructured":"Simonich, C. A. L. & Bloom, J. D. Pseudovirus deep mutational scanning of RSV Long F protein. Zenodo https:\/\/doi.org\/10.5281\/zenodo.21049419 (2026).","DOI":"10.5281\/zenodo.21049419"},{"key":"11030_CR72","doi-asserted-by":"publisher","first-page":"10678","DOI":"10.1128\/JVI.79.16.10678-10689.2005","volume":"79","author":"JH Schickli","year":"2005","unstructured":"Schickli, J. H., Kaur, J., Ulbrandt, N., Spaete, R. R. & Tang, R. S. An S101P substitution in the putative cleavage motif of the human metapneumovirus fusion protein is a major determinant for trypsin-independent growth in vero cells and does not alter tissue tropism in hamsters. J. Virol. 79, 10678\u201310689 (2005).","journal-title":"J. Virol."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-11030-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-11030-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-11030-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:02:30Z","timestamp":1792620150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-11030-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":72,"journal-issue":{"issue":"8137","published-print":{"date-parts":[[2026,10,22]]}},"alternative-id":["11030"],"URL":"https:\/\/doi.org\/10.1038\/s41586-026-11030-4","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.D.B. consults for Apriori Bio, GSK, Merck and Pfizer. J.D.B. holds stock options in the Vaccine Company. J.D.B. is an inventor on Fred Hutch licensed patents related to deep mutational scanning of viral proteins. H.Y.C. has served on advisory boards for Vir and Roche. The Bloom laboratory receives funding from Aceris Biosciences under a sponsored research agreement related to antibodies distinct from the ones analysed in the current study.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}